Deals In Depth: September 2018
Executive Summary
In a $663 million alliance, Takeda and Molecular Templates will co-develop CD38-targeted engineered toxin bodies for multiple sclerosis and other diseases. Medtronic paid $1.3 billion to buy the rest of Israeli device maker Mazor Robotics. Biopharma financing was up from the previous month, thanks to a strong showing of FOPOs.